Study of Corneas Undergoing Balanced Salt Solution(BSS ®) Versus Glucose-bicarbonate-Ringer Lactate in Cataract Surgery
Primary Purpose
Cataract
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Phacoemulsification cataract surgery
Glucose-bicarbonate-Ringer Lactate (GBRL)
Balanced Salt Solution (BSS®)
Sponsored by
About this trial
This is an interventional treatment trial for Cataract focused on measuring Corneal endothelium, Cataract surgery, Irrigation solutions intraocular, Phacoemulsification
Eligibility Criteria
Inclusion Criteria:
- Uncomplicated senile cataract
- Visual acuity (VA) between 20/40 and 20/400
- Healthy corneas
Exclusion Criteria:
- Mental incapacity
- Patients with coexisting diseases of the cornea
- Presence of corneal opacity
- Uncontrolled glaucoma
- Uncontrolled diabetes mellitus
- Uveitis
- Cells or flare in the anterior chamber
- Prior intraocular surgery
- Patients using topical steroids or systemic
- Traumatic cataract, hereditary or toxic
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Balanced Salt Solution (BSS®)
Glucose-bicarbonate-Ringer Lactate (GBRL)
Arm Description
Subjects who received Balanced Salt Solution.
Subjects who received glucose-bicarbonate-Ringer Lactate.
Outcomes
Primary Outcome Measures
Increase in central corneal thickness (CCT)
Increase in central corneal thickness (CCT)
Increase in central corneal thickness (CCT)
Decrease in the percentage of endothelial cell density (ECD)
Decrease in the percentage of endothelial cell density (ECD)
Decrease in the percentage of endothelial cell density (ECD)
Secondary Outcome Measures
Full Information
NCT ID
NCT01334658
First Posted
April 8, 2011
Last Updated
April 12, 2011
Sponsor
Grupo de Estudos em Oftalmologia Clínica e Cirúrgica
Collaborators
CLIHON
1. Study Identification
Unique Protocol Identification Number
NCT01334658
Brief Title
Study of Corneas Undergoing Balanced Salt Solution(BSS ®) Versus Glucose-bicarbonate-Ringer Lactate in Cataract Surgery
Official Title
Study of Endothelial Cell Density of Corneas Undergoing Phacoemulsification Surgery Using Balanced Salt Solution (BSS ®) Versus Glucose-bicarbonate-Ringer Lactate as Irrigating Solution: a Randomized Clinical Trial.
Study Type
Interventional
2. Study Status
Record Verification Date
April 2011
Overall Recruitment Status
Completed
Study Start Date
August 2010 (undefined)
Primary Completion Date
February 2011 (Actual)
Study Completion Date
February 2011 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Grupo de Estudos em Oftalmologia Clínica e Cirúrgica
Collaborators
CLIHON
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a study aimed at evaluating the effectiveness and impact of two intraocular irrigating solution (BSS ® versus glucose-bicarbonate-Ringer Lactate - GBRL) on the health of the cornea after cataract surgery by phacoemulsification.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cataract
Keywords
Corneal endothelium, Cataract surgery, Irrigation solutions intraocular, Phacoemulsification
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
64 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Balanced Salt Solution (BSS®)
Arm Type
Active Comparator
Arm Description
Subjects who received Balanced Salt Solution.
Arm Title
Glucose-bicarbonate-Ringer Lactate (GBRL)
Arm Type
Active Comparator
Arm Description
Subjects who received glucose-bicarbonate-Ringer Lactate.
Intervention Type
Procedure
Intervention Name(s)
Phacoemulsification cataract surgery
Intervention Description
A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.
All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).
Intervention Type
Drug
Intervention Name(s)
Glucose-bicarbonate-Ringer Lactate (GBRL)
Intervention Description
A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.
All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).
Intervention Type
Drug
Intervention Name(s)
Balanced Salt Solution (BSS®)
Intervention Description
A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.
All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).
Primary Outcome Measure Information:
Title
Increase in central corneal thickness (CCT)
Time Frame
Two days after surgery.
Title
Increase in central corneal thickness (CCT)
Time Frame
Thirty days after surgery.
Title
Increase in central corneal thickness (CCT)
Time Frame
Ninety days after surgery.
Title
Decrease in the percentage of endothelial cell density (ECD)
Time Frame
Two days after surgery.
Title
Decrease in the percentage of endothelial cell density (ECD)
Time Frame
Thirty days after surgery.
Title
Decrease in the percentage of endothelial cell density (ECD)
Time Frame
Ninety days after surgery.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Uncomplicated senile cataract
Visual acuity (VA) between 20/40 and 20/400
Healthy corneas
Exclusion Criteria:
Mental incapacity
Patients with coexisting diseases of the cornea
Presence of corneal opacity
Uncontrolled glaucoma
Uncontrolled diabetes mellitus
Uveitis
Cells or flare in the anterior chamber
Prior intraocular surgery
Patients using topical steroids or systemic
Traumatic cataract, hereditary or toxic
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hermelino L Oliveira Neto
Organizational Affiliation
CLIHON
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Israel C Marques Neto
Organizational Affiliation
State University of Feira de Santana (UEFS)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Brunno B Barros
Organizational Affiliation
State University of Feira de Santana (UEFS)
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Study of Corneas Undergoing Balanced Salt Solution(BSS ®) Versus Glucose-bicarbonate-Ringer Lactate in Cataract Surgery
We'll reach out to this number within 24 hrs